Long-term immunoprophylaxis by TLR9 ligand mediates macrophage-ILC cross-talk against respiratory viral infection.
Start here
The study found that a single intranasal dose of K3-SPG, a TLR9 ligand CpG oligodeoxynucleotide-schizophyllan complex, protected hosts against lethal respiratory virus infection for 100 days, independent of antigen-specific immunity.
Excerpted from Science Advances
Coverage timeline
Follow the coverage to see the different angles.
- Science AdvancesPickLong-term immunoprophylaxis by TLR9 ligand mediates macrophage-ILC cross-talk against respiratory viral infection.
The study found that a single intranasal dose of K3-SPG, a TLR9 ligand CpG oligodeoxynucleotide-schizophyllan complex, protected hosts against lethal respiratory virus infection for 100 days, independent of antigen-specific immunity.
Coverage and heat for this story
Reports so far 1·Heat now 8·Peak heat 10 (Oct 19 03:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.